+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adult Myopia - Epidemiology Forecast to 2030

  • ID: 5307000
  • Report
  • March 2021
  • Region: Global
  • 100 pages
  • DelveInsight
This ‘Adult Myopia-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology Adult Myopia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adult Myopia Disease Understanding

Myopia refers to a spectrum of ocular disorders in which the far point of the eye is closer to the retina than infinity. It is becoming a worldwide epidemic and imposes a tremendous public health burden. As a consequence, the global initiative for the elimination of avoidable blindness has grouped refractive error as one of five leading causes of blindness and visual impairment in the world.

Myopia can be categorized by severity and age of onset. Severity is often categorized as low myopia (between − 0.50 and − 2.99 D), moderate myopia (between − 3.00 and − 5.99 D), and high myopia as worse than or equal to − 6.00 D. The signs and symptoms for myopia include squinting, feeling fatigued when driving or playing sports along with headache and strain.

Age is one of the major risk factors for myopia and visual stress experienced by adults as a result of doing detailed work, such as reading or using a computer leads to development and progression of myopia over time.

Myopia could lead to permanent loss of sight and it has been associated with complications, such as myopic macular degeneration, retinal detachment, cataract, and open angle glaucoma. These complications can lead to irreversible visual impairment later in life.

Myopia and its associated complications are an increasing public health concern. While glasses and contact lens correction are valuable in treating the symptomatic vision changes associated with myopia, they do not change the anatomic progression of the myopic eye. Low-dose atropine use (0.01%) remains the most encouraging treatment choice available at this time, though more studies are needed to identify its optimal use. Additional environmental studies will also help determine if there are lifestyle changes that could slow myopia's progression. In the meantime, vision screening and early detection remain essential for diagnosis and correction to avoid the loss of correctable, functional vision.

Adult Myopia Epidemiology

The Adult Myopia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Adult Myopia epidemiology segmented as the Total Prevalent Population of Adult Myopia and Prevalence of myopic choroidal neovascularization. The report includes the Prevalent scenario of Adult Myopia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Adult Myopia Epidemiology

The epidemiology segment also provides the Adult Myopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Adult Myopia Associated in 7MM countries was estimated to be 213,211,282 cases in 2020 and is expected to increase at a CAGR of 2% for the study period (2018-2030).
  • As per the estimates, United States has the highest Prevalent population of Adult Myopia
  • Among the EU5 countries, Germany had the highest prevalent population of Adult Myopia. On the other hand, Spain had the lowest number of cases as 13,248,758 cases in 2020.
Scope of the Report
  • Adult Myopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Adult Myopia Epidemiology Report and Model provide an overview of the risk factors and global trends of Adult Myopia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Adult Myopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Adult Myopia
  • The report provides the segmentation of the Adult Myopia epidemiology by Prevalent Cases of Adult Myopia in 7MM
  • The report provides the segmentation of the Adult Myopia epidemiology by Prevalent Cases of Myopic CNV in 7MM
Report Highlights
  • 10-year Forecast of Adult Myopia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Adult Myopia
  • Prevalent Cases according to segmentation: Prevalent Cases of Myopic CNV
KOL Views

The publisher interviews KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population about Adult Myopia?
  • What are the key findings of Adult Myopia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2018-2030)?
  • What would be the total number of patients with Adult Myopia across the 7MM during the forecast period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2018-2030)?
  • What are the disease risk, burden, and unmet needs of Adult Myopia?
  • What are the currently available treatments for Adult Myopia?
Reasons to Buy

The Adult Myopia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Adult Myopia market
  • Quantify patient populations in the global Adult Myopia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adult Myopia therapeutics in each of the markets covered
  • Understand the magnitude of Adult Myopia population by its Prevalence cases
  • Understand the magnitude of Adult Myopia population by its Types-specific cases
  • The Adult Myopia epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Adult Myopia Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

According to a study by Retina Today (2019), in 2010, an estimated 1.9 billion people (27% of the world's population) were myopic, and 70 million of them (2.8%) had high myopia. These numbers are projected to rise to 52% and 10%, respectively, by 2050.
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 Adult Myopia Market Overview at a Glance
3.1 Market Share (%) Distribution of Adult Myopia in 2018
3.2 Market Share (%) Distribution of Adult Myopia in 2030

4 Executive Summary of Adult Myopia

5 Disease Background and Overview
5.1 Introduction
5.2 Terminology and Classification
5.3 Causes
5.4 Risk Factors
5.5 Pathogenesis
5.6 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Diagnosed Prevalent Patient Population of Adult Myopia
6.3 Assumptions and Rationale
6.4 The United States
6.4.1 Prevalence of Adult Myopia in the United States
6.4.2 Prevalence of Myopic Choroidal neovascularization in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Prevalence of Adult Myopia in Germany
6.5.1.2 Prevalence of Myopic Choroidal neovascularization in Germany
6.5.2 France
6.5.2.1 Prevalence of Adult Myopia in France
6.5.2.2 Prevalence of Myopic Choroidal neovascularization in France
6.5.3 Italy
6.5.3.1 Prevalence of Adult Myopia in Italy
6.5.3.2 Prevalence of Myopic Choroidal neovascularization in Italy
6.5.4 Spain
6.5.4.1 Prevalence of Adult Myopia in Spain
6.5.4.2 Prevalence of Myopic Choroidal neovascularization in Spain
6.5.5 United Kingdom
6.5.5.1 Prevalence of Adult Myopia in the United Kingdom
6.5.5.2 Prevalence of Myopic Choroidal neovascularization in the United Kingdom
6.6 Japan
6.6.1 Prevalence of Adult Myopia in Japan
6.6.2 Prevalence of Myopic Choroidal neovascularization in Japan

7 Appendix
7.1 Bibliography
7.2 Report Methodology

8 Publisher Capabilities

9 Disclaimer

10 About the Publisher

List of Tables
Table 1: Summary of Adult Myopia, Market, Epidemiology, and Key Events (2018-2030)
Table 2: A proposed international photographic classification and grading system for myopic macular degeneration
Table 3: Prevalent Patient Population of Adult Myopia in thousands in 7MM (2018-2030)
Table 4: Prevalence of Adult Myopia in thousands in the United States (2018-2030)
Table 5: Prevalence of Myopic Choroidal neovascularization in the United States (2018-2030)
Table 6: Prevalence of Adult Myopia in thousands in Germany (2018-2030)
Table 7: Prevalence of Myopic Choroidal neovascularization in Germany (2018-2030)
Table 8: Prevalence of Adult Myopia in thousands in France (2018-2030)
Table 9: Prevalence of Myopic Choroidal neovascularization in France (2018-2030)
Table 10: Prevalence of Adult Myopia in thousands in Italy (2018-2030)
Table 11: Prevalence of Myopic Choroidal neovascularization in Italy (2018-2030)
Table 12: Prevalence of Adult Myopia in thousands in Spain (2018-2030)
Table 13: Prevalence of Myopic Choroidal neovascularization in Spain (2018-2030)
Table 14: Prevalence of Adult Myopia in thousands in the United Kingdom (2018-2030)
Table 15: Prevalence of Myopic Choroidal neovascularization in the UK (2018-2030)
Table 16: Prevalence of Adult Myopia in thousands in Japan (2018-2030)
Table 17: Prevalence of Myopic Choroidal Neovascularization in Japan (2018-2030)

List of Figures
Figure 1: Myopic Eye vs. Normal Eye
Figure 2: Progression of myopic macular degeneration in a group of people with high myopia (≤ −8.00 D)
Figure 3: Prevalent Patient Population of Adult Myopia in thousands in 7MM (2018-2030)
Figure 4: Prevalent Patient Population of Myopic Choroidal neovascularization in thousands in 7MM (2018-2030)
Figure 5: Prevalence of Adult Myopia in thousands in the United States (2018-2030)
Figure 6: Prevalence of Myopic Choroidal neovascularization in the United States (2018-2030)
Figure 7: Prevalence of Adult Myopia in thousands in Germany (2018-2030)
Figure 8: Prevalence of Myopic Choroidal neovascularization in Germany (2018-2030)
Figure 9: Prevalence of Adult Myopia in thousands in France (2018-2030)
Figure 10: Prevalence of Myopic Choroidal neovascularization in France (2018-2030)
Figure 11: Prevalence of Adult Myopia in thousands in Italy (2018-2030)
Figure 12: Prevalence of Myopic Choroidal neovascularization in Italy (2018-2030)
Figure 13: Prevalence of Adult Myopia in thousands in Spain (2018-2030)
Figure 14: Prevalence of Myopic Choroidal neovascularization in Spain (2018-2030)
Figure 15: Prevalence of Adult Myopia in thousand in the United Kingdom (2018-2030)
Figure 16: Prevalence of Myopic Choroidal neovascularization in the UK (2018-2030)
Figure 17: Prevalence of Adult Myopia in thousands in Japan (2018-2030)
Figure 18: Prevalence of Myopic Choroidal Neovascularization in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll